Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction

PHASE2CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

March 31, 2006

Study Completion Date

September 30, 2006

Conditions
Myocardial Infarction
Interventions
DRUG

Magnevist (Gadopentetate dimeglumine, BAY86-4882)

One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period1:Magnevist 0.1 mmol/kg body weightperiod 2: Magnevist 0.2 mmol/kg body weight

DRUG

Magnevist (Gadopentetate dimeglumine, BAY86-4882)

One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period 1: Magnevist 0.2 mmol/kg body weightperiod 2: Magnevist 0.1 mmol/kg body weight

Trial Locations (7)

17033

Hershey

27103

Winston-Salem

74133

Tulsa

92103

San Diego

97239

Portland

15212-4772

Pittsburgh

C1428BKN

Buenos Aires

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY